11 research outputs found

    Prognostic value of microRNAs in head and neck cancers: a systematic review and meta-analysis protocol

    No full text
    Abstract Background Head and neck cancers form a significant share of all cancer incidences worldwide. Though treatment modalities exist, post-treatment recurrence and survival rates in recurrent patients continue to be high. MiRNAs offer an effective method of estimating the probability of recurrence and survival of HNC patients, thereby allowing for effective treatment and better survival rates. Methods The systematic review protocol was prepared according to the Preferred Reporting Items for Systematic Review and Meta-Analyses Protocols (PRISMA-P) 2015 statement. Relevant studies will be identified by a rigorous search of multiple bibliographical databases, including MEDLINE, Scopus, PubMed, Web of Science, Embase and Science Direct, without any language restrictions (up to June 2018). The primary screening will be performed by a review team via analysis of titles and abstracts of published articles. Final selection of articles will be achieved by two independent reviewers, based on predefined selection criteria. Data will be extracted from eligible studies using a pre-piloted data extraction form. Statistical analysis will be performed on the basis of available data, extracted from eligible studies. Meta-analysis will be performed, and a forest plot will be generated, to determine pooled hazard ratios (HR) and 95% confidence interval (CI) using CMA. A fixed or random-effects model of meta-analysis will be used depending upon the between-study heterogeneity; publication bias will be determined by the Egger’s bias indicator test. A narrative synthesis will be undertaken where statistical data is found to be insufficient. Discussion There is a lack of highly sensitive and specific biomarkers for estimating the HNC patients’ prognostic outcomes, particularly in post-treatment conditions. This systematic review will identify and validate specific miRNA as prognostic biomarkers by utilising a collection of previously published data on miRNA expression and survival. Highlighting these prognostic specific miRNAs will have major clinical implications by allowing for better overall treatment strategies and patient survival estimates, by offering clinicians a method of quantitatively analysing prognosis via miRNA expression. Systematic review registration This review protocol was registered on PROSPERO and assigned the registration number CRD42017077411

    Letter to the editor: is HIF-1α a viable prognostic indicator in OSCC? A critical review of a meta-analysis study

    No full text
    Abstract The study performed by Zhou et al. (World J Surg Oncol 15:104, 2017) titled “Clinical and prognostic significance of HIF-1α overexpression in oral squamous cell carcinoma: a meta-analysis” attempts to highlight hypoxia-inducible factor-1 alpha as a possible prognostic marker in oral squamous cell carcinoma (OSCC). We would like to underline a few points which may affect such a conclusion. The correlations between HIF-1α expression and tumour size as well as tumour stage are debatable. Further, the subgroup analysis incorporating Australia and Europe into a single subgroup limits the viability of the prognostic analysis of HIF-1α. We also suggest future studies in the same research area to analyse head and neck squamous cell carcinoma instead of OSCC, to ameliorate the limitations encountered by Zhou et al., due to the scarcity of relevant clinical data and a low number of studies about OSCC

    Downregulation of Notch4 – a prognostic marker in distinguishing oral verrucous carcinoma from oral squamous cell carcinoma

    No full text
    Introduction: Oral verrucous carcinoma is a special form of well-differentiated squamous cell carcinoma which possesses specific clinical, morphologic and cytokinetic features that differ from other types of oral cancers and hence diagnosis requires immense experience in histopathology. Hence it is certainly important to distinguish such a lesion from other oral tumors as treatment strategies vary widely between them. Objective: In search of a critical diagnostic marker in distinguishing oral verrucous carcinoma from oral squamous cell carcinoma, Notch4 receptor, one of the key regulatory molecules of the Notch signaling family has been aberrantly activated in the progression of several types of tumors. However its function in oral verrucous carcinoma remains unexplored. Thus the present study aims in determining the differential expression pattern of Notch4 in oral verrucous carcinoma and oral squamous cell carcinoma. Methods: Ten patients reported positive for oral cancer (5 patients with oral verrucous carcinoma and 5 patients with oral squamous cell carcinoma). Five normal tissue samples were also obtained and evaluated for clinicopathological parameters and immunohistochemistry, western blotting and real time polymerase chain reaction for Notch4 expression. Results: Our results reveal that the expression of Notch4 was considerably high in oral squamous cell carcinoma lesions compared to normal tissue, whereas in oral verrucous carcinoma, irrespective of the clinicopathological features, complete regulação descendente of Notch4 was observed. Conclusions: These preliminary findings strongly support the fact that Notch4 is downregulated in oral verrucous carcinoma and could be considered as a suitable prognostic marker in distinguishing oral verrucous carcinoma from oral squamous cell carcinoma. This distinguishing marker can help in improving therapeutic options in patients diagnosed with oral verrucous carcinoma. Resumo: Introdução: O carcinoma verrucoso de cavidade oral Ă© uma forma especial de carcinoma de cĂ©lulas escamosas bem diferenciada que tem caracterĂ­sticas clĂ­nicas, morfolĂłgicas e citocinĂ©ticas especĂ­ficas que diferem de outros tipos de cĂąnceres orais. Por essa razĂŁo, o diagnĂłstico requer grande experiĂȘncia em histopatologia. Portanto, Ă© certamente importante distingui-lo de outros tumores orais, pois as respectivas estratĂ©gias de tratamento variam muito. Objetivo: Em busca de um marcador de diagnĂłstico crĂ­tico na distinção entre o carcinoma verrucoso e o carcinoma de cĂ©lulas escamosas de cavidade oral, o receptor Notch4, uma das principais molĂ©culas reguladoras da famĂ­lia de sinalizadores Notch, foi ativado de maneira anormal na progressĂŁo de vĂĄrios tipos de tumores. No entanto, sua função no carcinoma verrucoso permanece inexplorada. Assim, o presente estudo tem como objetivo determinar o padrĂŁo de expressĂŁo diferencial de Notch4 no carcinoma verrucoso e de cĂ©lulas escamosas de cavidade oral. MĂ©todo: Dez pacientes tiveram resultado positivo para cĂąncer oral (cinco pacientes com carcinoma verrucoso e cinco pacientes com carcinoma de cĂ©lulas escamosas) e cinco amostras normais foram tambĂ©m obtidas. AlĂ©m da avaliação dos parĂąmetros clĂ­nico-patolĂłgicos, foram feitos anĂĄlise imuno-histoquĂ­mica, Western Blot e reação de polimerase em cadeia em tempo real para a expressĂŁo de Notch4. Resultados: Nossos resultados revelam que a expressĂŁo de Notch4 foi consideravelmente alta em carcinomas de cĂ©lulas escamosas em comparação com os tecidos normais, enquanto que no carcinoma verrucoso, independentemente das caracterĂ­sticas clĂ­nico-patolĂłgicas, observou-se regulação descendente completa de Notch4. ConclusĂŁo: Esses achados preliminares apoiam fortemente o fato de que Notch4 estava regulado para baixo no carcinoma verrucoso oral e poderia ser considerado um marcador prognĂłstico adequado para distinguir entre carcinoma verrucoso e carcinoma de cĂ©lulas escamosas de cavidade oral. Esse marcador distintivo pode ajudar a melhorar as opçÔes terapĂȘuticas em pacientes com diagnĂłstico de carcinoma verrucoso oral. Keywords: Oral verrucous carcinoma, Oral squamous cell carcinoma, Notch4, Prognostic marker, Palavras-chave: Carcinoma verrucoso oral, Carcinoma de cĂ©lulas escamosas oral, Notch4, Marcador prognĂłstic

    Exosome DNA: An untold story of cancer

    No full text
    Abstract Exosome is nanosized tiny membrane‐bound vesicles and is a subpopulation of extracellular vesicles (EVs). In general, it participates in intercellular communication and acts as a messenger of several pathological complications. Exosome and cancer interlink is the most exciting domain of current cancer research. The internal molecular cargos (proteins, lipids, metabolites, miRNA, and DNA) of tumor derived exosomes (TEXs) are capable of transforming normal cells into tumor phenotypes. Exosome DNA is the less explored area of EVs research. It is involved in several events in cancer progression such as uncontrol cell growth, reprogramming of immune cells, metastasis, and therapeutic resistance. Exo‐DNA is also involved in epigenetic alteration, which promotes cancer. It has a great impact on cancer theranostics (biomarker and therapeutics) research. Exo‐DNA‐based cancer examination supports more detailed cancer research

    Detection of embryonic stem cell markers in adult human adipose tissue-derived stem cells

    No full text
    Background: Bone marrow transplantation is already an established therapy, which is now widely used in medicine to treat leukemia, lymphoma, and several inherited blood disorders. The culture of multilineage cells from easily available adipose tissue is another source of multipotent mesenchymal stem cells, and is referred to as adipose tissue-derived stem cells (ADSCs). While ADSCs are being used to treat various conditions, some lacuna exists regarding the specific proteins in these. It was therefore decided to analyze the specific proteins of embryonic cells in ADSCs. Aims: To analyze the specific protein of embryonic stem cells (ESCs) in ADSCs. Materials and Methods: Adult human adipose tissue-derived stem cells (ADSCs) were harvested from 13 patients after obtaining patientsâ€Č consent. The specific markers of ESCs included surface proteins CD10, CD13, CD44, CD59, CD105, and CD166, and further nucleostemin,(NS) NANOG, peroxisome proliferator-activated receptor-gÎł, collagen type 1 (Coll1), alkaline phosphate, (ALP) osteocalcin (OC), and core binding factor 1 (Cbfa1) were analyzed using by reverse transcription-polymerase chain reaction, (RT-PCR) immunofluorescence (IF), and western blot. Results: All the proteins were expressed distinctly, except CD13 and OC. CD13 was found individually with different expressions, and OC expression was discernable. Conclusions: Although the ESC with its proven self-renewal capacity and pluripotency seems appropriate for clinical use, the recent work on ADSCs suggests that these adult stem cells would be a valuable source for future biotechnology, especially since there is a relative ease of procurement

    Exosome: A megastar of future cancer personalized and precision medicine

    No full text
    Abstract Extracellular vesicles (EVs) are an innovative orientation of next‐generation cancer medicine. In EVs, the exosome is the most exciting domain associated with cancer research current decade.Exosomes have both cancer progression related and cancer healing capabilities depending on the source. It develops a new platform for cancer personalized and precision medicine visionary project to come to reality

    Exosome-based smart drug delivery tool for cancer theranostics

    No full text
     Exosomes are the phospholipid-membrane-bound subpopulation of extracellular vesicles derived from the plasma membrane. The main activity of exosomes is cellular communication. In cancer, exosomes play an important rolefrom two distinct perspectives, one related to carcinogenesis and the other as theragnostic and drug delivery tools. The outer phospholipid membrane of Exosome improves drug targeting efficiency. . Some of the vital features of exosomes such as biocompatibility, low toxicity, and low immunogenicity make it a more exciting drug delivery system. Exosome-based drug delivery is a new innovative approach to cancer treatment. Exosome-associated biomarker analysis heralded a new era of cancer diagnostics in a more specific way. This Review focuses on exosome biogenesis, sources, isolation, interrelationship with cancer and exosome-related cancer biomarkers, drug loading methods, exosome-based biomolecule delivery, advances and limitations of exosome-based drug delivery, and exosome-based drug delivery in clinical settings studies. The exosome-based understanding of cancer will change the diagnostic and therapeutic approach in the future.</p
    corecore